Therefore, to investigate the effects of NLRP3 blockade we utilized THP-1, hMonocytes, hMDM and iMGL from donors of a healthy aging cohort and ALS patients carrying various SOD1 pathogenic mutations. The gene discussed is NLRP3; the disease is amyotrophic lateral sclerosis.